ZA200907306B - Tetrahydroquinoline derivatives and use of same for treating cancer - Google Patents

Tetrahydroquinoline derivatives and use of same for treating cancer

Info

Publication number
ZA200907306B
ZA200907306B ZA200907306A ZA200907306A ZA200907306B ZA 200907306 B ZA200907306 B ZA 200907306B ZA 200907306 A ZA200907306 A ZA 200907306A ZA 200907306 A ZA200907306 A ZA 200907306A ZA 200907306 B ZA200907306 B ZA 200907306B
Authority
ZA
South Africa
Prior art keywords
same
treating cancer
tetrahydroquinoline derivatives
tetrahydroquinoline
derivatives
Prior art date
Application number
ZA200907306A
Other languages
English (en)
Inventor
Kai Schiemann
Dirk Finsinger
Christiane Amendt
Frank Zenke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200907306B publication Critical patent/ZA200907306B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200907306A 2007-03-20 2009-10-19 Tetrahydroquinoline derivatives and use of same for treating cancer ZA200907306B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007013854A DE102007013854A1 (de) 2007-03-20 2007-03-20 Tetrahydrochinoline

Publications (1)

Publication Number Publication Date
ZA200907306B true ZA200907306B (en) 2010-07-28

Family

ID=39692561

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907306A ZA200907306B (en) 2007-03-20 2009-10-19 Tetrahydroquinoline derivatives and use of same for treating cancer

Country Status (15)

Country Link
US (1) US20100076012A1 (xx)
EP (1) EP2121706A1 (xx)
JP (1) JP2010521505A (xx)
KR (1) KR20090130071A (xx)
CN (1) CN101636401A (xx)
AR (1) AR065786A1 (xx)
AU (1) AU2008228570A1 (xx)
BR (1) BRPI0808742A2 (xx)
CA (1) CA2681261A1 (xx)
DE (1) DE102007013854A1 (xx)
EA (1) EA200901180A1 (xx)
IL (1) IL200966A0 (xx)
MX (1) MX2009009917A (xx)
WO (1) WO2008113456A1 (xx)
ZA (1) ZA200907306B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084439A1 (en) * 2009-12-17 2011-07-14 Sanofi Tetrahydrocarboline derivatives as eg5 inhibitors
CN103328449A (zh) * 2011-01-26 2013-09-25 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
JP6521387B2 (ja) * 2014-04-18 2019-05-29 武田薬品工業株式会社 縮合複素環化合物
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
AU2016215432B2 (en) 2015-02-02 2020-07-30 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172104A (en) 1960-06-27 1965-03-02 Giannini Controls Corp Measurement of hypersonic flight data
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5428051A (en) 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6172104B1 (en) 1998-08-20 2001-01-09 The University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
DE69933890T2 (de) 1998-09-17 2007-03-15 University Of North Carolina At Chapel Hill Antimykotische wirkung von dikationischen molekülen
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US7250423B2 (en) 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
ATE507220T1 (de) 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline

Also Published As

Publication number Publication date
AU2008228570A1 (en) 2008-09-25
BRPI0808742A2 (pt) 2014-08-12
MX2009009917A (es) 2009-10-19
KR20090130071A (ko) 2009-12-17
CN101636401A (zh) 2010-01-27
JP2010521505A (ja) 2010-06-24
US20100076012A1 (en) 2010-03-25
AR065786A1 (es) 2009-07-01
EA200901180A1 (ru) 2010-04-30
CA2681261A1 (en) 2008-09-25
EP2121706A1 (de) 2009-11-25
WO2008113456A1 (de) 2008-09-25
IL200966A0 (en) 2010-05-17
DE102007013854A1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
HK1254895A1 (zh) 苄基苯衍生物及使用方法
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
PT2365802T (pt) Microcápsulas de rapamicina e utilização para o tratamento de cancro
EP2310526A4 (en) COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CANCER
HK1148906A1 (en) Compositions and methods for cancer treatment
ZA201001194B (en) Heterocyclic amides useful for the treatment of cancer and psoriasis
HK1140944A1 (en) Methods and compositions for treating recurrent cancer
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
EP2318406A4 (en) THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES
EP2497471A4 (en) USE OF BENZO-HETEROCYCLUS DERIVATIVES FOR PROPHYLAXIS AND TREATMENT OF CANCER OR FOR INHIBITION OF CANCER METASTAS
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
ZA201004134B (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1143157A1 (en) 4-pyridinone compounds and their use for cancer 4-
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2171086A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2225364A4 (en) CLASSIFICATION OF CANCER AND METHODS OF USE
IL199689A0 (en) Compounds and method for treatment of cancer
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
ZA200907306B (en) Tetrahydroquinoline derivatives and use of same for treating cancer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
GB2465907B (en) VHZ for diagnosis and treatment of cancer